
News|Articles|February 3, 2026
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
This case study leverages IQVIA data and analytics to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds where a 22 percentage point claim approval rate lift was observed, on average, helping mitigate decreasing access.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
Eli Lilly Generates $1.5 Billion Stockpile of Orforglipron Ahead of FDA Decision
2
Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron
3
Bridging the Data Gap: How Digital Behavioral Insights Can Transform HCP Targeting in Specialty Care
4
Pharm Exec's 2026 Pipeline Report: Next Frontiers in Focus
5